Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Medco Emerges As Big Winner In PBM Sweepstakes; Caremark Already Losing

  • News

Executive Summary

Medco may be the biggest beneficiary of the bidding war between pharmacy chain CVS and pharmacy benefit manager Express Scripts for PBM Caremark

You may also be interested in...



Caremark Rejects Express Scripts, Questions M&A History, Strategic Benefit

Caremark is highlighting Express Scripts' "questionable" record integrating prior acquisitions in trying to convince investors to support its proposed merger with pharmacy chain CVS

Caremark Rejects Express Scripts, Questions M&A History, Strategic Benefit

Caremark is highlighting Express Scripts' "questionable" record integrating prior acquisitions in trying to convince investors to support its proposed merger with pharmacy chain CVS

Express Scripts Makes Hostile Bid For Caremark, But Faces CVS, FTC Hurdles

Express Scripts will work to characterize the pharmacy benefit management marketplace as being composed of more players than the "big three" independent PBMs in attempting to secure Federal Trade Commission clearance of its proposed acquisition of Caremark, CEO George Paz indicated

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

See All
UsernamePublicRestriction

Register

PS047922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By